0001209191-15-009201.txt : 20150203
0001209191-15-009201.hdr.sgml : 20150203
20150203210013
ACCESSION NUMBER: 0001209191-15-009201
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150130
FILED AS OF DATE: 20150203
DATE AS OF CHANGE: 20150203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MYLAN INC.
CENTRAL INDEX KEY: 0000069499
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 251211621
STATE OF INCORPORATION: PA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1000 MYLAN BOULEVARD
CITY: CANONSBURG
STATE: PA
ZIP: 15317
BUSINESS PHONE: 724-514-1800
MAIL ADDRESS:
STREET 1: 1000 MYLAN BOULEVARD
CITY: CANONSBURG
STATE: PA
ZIP: 15317
FORMER COMPANY:
FORMER CONFORMED NAME: MYLAN LABORATORIES INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: FRM CORP
DATE OF NAME CHANGE: 19711003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COURY ROBERT J
CENTRAL INDEX KEY: 0001197543
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-09114
FILM NUMBER: 15573277
MAIL ADDRESS:
STREET 1: 1500 CORPORATE DRIVE
STREET 2: SUITE 400
CITY: CANONSBURG
STATE: PA
ZIP: 15317
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-01-30
0
0000069499
MYLAN INC.
MYL
0001197543
COURY ROBERT J
1000 MYLAN BLVD
CANONSBURG
PA
15317
1
1
0
0
Executive Chairman
Common Stock
2015-01-30
4
M
0
258564
21.13
A
1535254
D
Common Stock
2015-01-30
4
S
0
258564
53.7283
D
1276690
D
Common Stock
2015-02-02
4
M
0
130203
21.13
A
1406893
D
Common Stock
2015-02-02
4
M
0
273912
22.66
A
1680805
D
Common Stock
2015-02-02
4
S
0
404115
52.8739
D
1276690
D
Common Stock
2015-02-03
4
M
0
51903
22.66
A
1328593
D
Common Stock
2015-02-03
4
M
0
181035
23.44
A
1509628
D
Common Stock
2015-02-03
4
M
0
51502
30.90
A
1561130
D
Common Stock
2015-02-03
4
S
0
284440
51.0135
D
1276690
D
Common Stock
4957
I
By 401(k) Plan
Employee Stock Option - Right to Buy
21.13
2015-01-30
4
M
0
258564
0.00
D
2020-03-03
Common Stock
258564
144399
D
Employee Stock Option - Right to Buy
21.13
2015-02-02
4
M
0
130203
0.00
D
2020-03-03
Common Stock
130203
14196
D
Employee Stock Option - Right to Buy
22.66
2015-02-02
4
M
0
273912
0.00
D
2021-03-02
Common Stock
273912
56316
D
Employee Stock Option - Right to Buy
22.66
2015-02-03
4
M
0
51903
0.00
D
2021-03-02
Common Stock
51903
4413
D
Employee Stock Option - Right to Buy
23.44
2015-02-03
4
M
0
181035
0.00
D
2022-02-22
Common Stock
181035
4266
D
Employee Stock Option - Right to Buy
30.90
2015-02-03
4
M
0
51502
0.00
D
2023-03-06
Common Stock
51502
3236
D
Represents acquisition of Mylan common stock upon exercise of stock options granted on March 3, 2010.
Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on January 30, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 403,595 shares in transactions ranging from $53.01 to $54.00 with a weighted average price of $53.5684 as well as 205,341 shares in transactions ranging from $54.005 to $54.25 with a weighted average price of $54.0425. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
Represents acquisition of Mylan common stock upon exercise of stock options granted on March 2, 2011.
Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 2, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 937,763 shares in transactions ranging from $52.23 to $53.22 with a weighted average price of $52.8646 as well as 13,957 shares in transactions ranging from $53.23 to $53.745 with a weighted average price of $53.5027. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
Represents acquisition of Mylan common stock upon exercise of stock options granted on February 22, 2012.
Represents acquisition of Mylan common stock upon exercise of stock options granted on March 6, 2013.
Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 3, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 520,475 shares in transactions ranging from $52.50 to $53.25 with a weighted average price of $52.8739 as well as 149,400 shares at $53.50 and 1 share at $54.50. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
This option exercise and the related sale of the underlying common stock were executed pursuant to a 10b5-1 trading plan dated November 9, 2014.
These options vested in three equal installments on March 3, 2011, 2012, and 2013.
These options vested in three equal installments on March 2, 2012, 2013, and 2014.
Two thirds of these options vested in equal installments on February 22, 2013 and 2014.
One third of these options vested on March 6, 2014.
As disclosed in the proxy statement filed by Mylan Inc. ("Mylan") on December 24, 2014 and the Form 8-K filed by Mylan on November 5, 2014, the filing person has exercised the stock options shown on this Form 4 to mitigate the effects of the excise tax under Section 4985 of the Internal Revenue Code of 1986, as amended, in connection with the proposed acquisition (the "Transaction") by a new public company organized in the Netherlands of both Mylan and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business and has sold the shares reported on this Form 4 to mitigate the tax and other costs imposed as a result of such exercises and the Transaction.
/s/ Bradley L. Wideman, by power of attorney
2015-02-03